Therapy of leukocytoclastic (necrotizing) cutaneous vasculitis

Dermatologic Therapy

Volumn 14, Issue 2, 2001, Pages 95-101

  Piette, Warren W ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Skin; Therapy; Vasculitis

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ANAPHYLACTOID PURPURA; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DOSE RESPONSE; HEMOLYSIS; HUMAN; HYPERSENSITIVITY; LEUKOCYTOCLASTIC VASCULITIS; NECROTIZING ARTERITIS; PRURITUS; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0034995249     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1529-8019.2001.014002095.x     Document Type: Review

References (48)

1. Elimination diet in the treatment of selected patients with hypersensitivity vasculitis
2. Management issues in vasculitis
3. Management of necrotizing vasculitis with colchicine: Improvement in patients with cutaneous lesions and Behcet's syndrome
4. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis
5. A clinical approach to the vasculitis patient in the dermatologic office
6. Henoch-Schonlein purpura: Successful treatment with dapsone
7. Dapsone-associated agranulocytosis and severe anemia in a patient with leukocytoclastic vasculitis
8. Recombinant granulocyte colony-stimulating factor for dapsone-induced agranulocytosis in leukocytoclastic vasculitis
9. Chronic, recurrent small-vessel cutaneous vasculitis: Clinical experience in 13 patients
10. Urticarial vasculitis
11. Cutaneous necrotizing vasculitis
12. Persistent urticarial eruption in an asthmatic patient
13. The normocomplementemic urticarial vasculitis syndrome - Report of a case and response to colchicine
14. The hypocomplementemic urticarial-vasculitis syndrome: Therapeutic response to hydroxychloroquine
15. Less common treatment in cutaneous vasculitis
16. What is Schonlein-Henoch purpura, and why should we care?
17. Schonlein-Henoch purpura in adult patients: Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases
18. Henoch-Schonlein purpura in children. Report of 100 patients and review of the literature
19. Henoch-Schonlein purpura: The Chandigarh experience
20. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy
21. Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: A clinical and histopathological study
22. Cutaneous small-vessel vasculitis
23. Immunosuppressive therapy in cutaneous vasculitis
24. Immunosuppressive agents in dermatology
25. Azathioprine: An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous leukocytoclastic vasculitis
26. Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis
27. Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case
28. Azathioprine-induced multisystem organ failure and cardiogenic shock
29. Azathioprine hypersensitivity-like reactions - A case report and a review of the literature
30. Desensitization to azathioprine
31. Low-dose methotrexate controls a severe form of polyarteritis nodosa
32. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: Cutaneous polyarteritis nodosa and Behcet's disease
33. Methotrexate-induced necrolysis
34. Methotrexate-induced epidermal necrosis
35. Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths)
36. Methotrexate-induced exacerbation of urticarial vasculitis: An unusual adverse reaction
37. Cutaneous necrotizing vasculitis after low dose methotrexate therapy for rheumatoid arthritis: A possible manifestation of methotrexate hypersensitivity
38. Wegener's granulomatosis
39. New treatments of ANCA-associated vasculitis
40. Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: Experience in four cases
41. Induction of remission in Wegener's granulomatosis with low dose methotrexate
42. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis
43. Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice
44. New concepts in treatment protocols for severe systemic vasculitis
45. Primary systemic vasculitis
46. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin
47. Virus-associated vasculitides
48. Common mistakes in the clinical approach to vasculitis